BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Target Price of $125.80 According to Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have received a consensus recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $125.80.

A number of analysts have recently issued reports on BNTX shares. Canaccord Genuity Group reduced their price objective on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Bank of America reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd.

Insider Buying and Selling at BioNTech

In related news, CEO Ugur Sahin sold 72,000 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the sale, the chief executive officer owned 108,209 shares in the company, valued at approximately $10,521,161.07. This trade represents a 39.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock valued at $79,246,837 over the last three months. Corporate insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On BioNTech

Institutional investors and hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in BioNTech during the second quarter valued at $39,000. Farther Finance Advisors LLC lifted its stake in BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock worth $48,000 after purchasing an additional 118 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of BioNTech by 50.3% during the 3rd quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock valued at $83,000 after purchasing an additional 282 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in shares of BioNTech by 328.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after purchasing an additional 1,423 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. grew its position in shares of BioNTech by 232.8% during the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock valued at $188,000 after purchasing an additional 1,341 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech reported Q3 earnings of $1.99 per share, above the $0.85 consensus estimate, and revenue of $1.49 billion, ahead of the $1.17 billion expected. The company also returned to profitability for the quarter. BioNTech Reports Q3 Net Profit; Revenue Falls 15% On Lower COVID-19 Vaccine Demand
• Positive Sentiment: The company raised its 2026 revenue guidance, setting a range of €1.7 billion to €1.9 billion and lifting the midpoint. It ended the quarter with €16.2 billion in cash, cash equivalents and securities, providing substantial resources for development. BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: BioNTech highlighted oncology progress, including trial data showing gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer. An interim analysis is anticipated before year-end. BioNTech outlines 2026 revenue guidance
• Neutral Sentiment: The company launched its updated COVID-19 vaccine for the 2026/2027 season in multiple regions, but the financial contribution will depend on demand. BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Negative Sentiment: Despite beating estimates, quarterly revenue fell 15.1% year over year, with lower COVID-19 vaccine demand cited as a factor. Reports also flagged pipeline setbacks, which could temper optimism about BioNTech’s transition toward oncology growth. BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks

BioNTech Stock Down 0.7%

NASDAQ BNTX opened at $86.92 on Wednesday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $21.98 billion, a P/E ratio of -11.10 and a beta of 1.28. The stock’s 50-day moving average price is $96.14 and its 200-day moving average price is $96.99.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.60) earnings per share. On average, equities research analysts predict that BioNTech will post -6.62 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.